Table 1.

Definitions of Cancer Therapy‐Related Cardiotoxicity by Different Cardiovascular and Oncology Societies and Research Groups

Society/Organization	Definition	Anticancer drug	Imaging modality
The American Society of Echocardiography and the European Association of Cardiovascular Imaging 36	Decrease in the left ventricular ejection fraction >10%, to a value <53%, confirmed with repeat imaging 2–3 wk later	Any	Echocardiography, cardiac magnetic resonance imaging, multigated radionuclide angiography (MUGA)
Food and Drug Administration 37	Decrease in the left ventricular ejection fraction ≥10% to below the lower limit of normal (or absolute left ventricular ejection fraction ≤45%), or ≥20% absolute decline	Doxorubicin	MUGA or echocardiography
National Cancer Institute 38	Common Terminology Criteria for Adverse Events: Grade 1: asymptomatic elevation in biomarkers or abnormalities on imaging Grade 2: symptoms with mild exertion Grade 3: symptoms with moderate exertion Grade 4: severe, life‐threatening symptoms requiring hemodynamic support Grade 5: death	Any	Not specified
Breast Cancer International Research Group 39	Relative reduction in left ventricular ejection fraction >10% from baseline	Trastuzumab and doxorubicin	MUGA or echocardiography
Herceptin Adjuvant Trial Study Team 40	Reduction in left ventricular ejection fraction ≥10% to <50% at any time	Trastuzumab	MUGA or echocardiography
Cardiac Review and Evaluation Committee 35	Reduction in left ventricular ejection fraction ≥5% to <55% when accompanies by heart failure signs and symptoms, or a decrease ≥10% to <55% without signs and symptoms	Trastuzumab and doxorubicin	MUGA or echocardiography